217 related articles for article (PubMed ID: 7790111)
1. Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes.
Wang Q; Redovan C; Tubbs R; Olencki T; Klein E; Kudoh S; Finke J; Bukowski RM
Int J Cancer; 1995 Jun; 61(6):780-5. PubMed ID: 7790111
[TBL] [Abstract][Full Text] [Related]
2. Expression of cytokine mRNA transcripts in renal cell carcinoma.
Olive C; Cheung C; Nicol D; Falk MC
Immunol Cell Biol; 1998 Aug; 76(4):357-62. PubMed ID: 9723777
[TBL] [Abstract][Full Text] [Related]
3. Enhanced expression of IFN-gamma mRNA in CD4(+)or CD8(+)tumour-infiltrating lymphocytes compared to peripheral lymphocytes in patients with renal cell cancer.
Elsässer-Beile U; Rindsfüser M; Grussenmeyer T; Schultze-Seemann W; Wetterauer U
Br J Cancer; 2000 Sep; 83(5):637-41. PubMed ID: 10944605
[TBL] [Abstract][Full Text] [Related]
4. Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes.
Maeurer MJ; Martin DM; Castelli C; Elder E; Leder G; Storkus WJ; Lotze MT
Cancer Immunol Immunother; 1995 Aug; 41(2):111-21. PubMed ID: 7656270
[TBL] [Abstract][Full Text] [Related]
5. Interferon-gamma production by T lymphocytes from renal cell carcinoma patients: evidence of impaired secretion in response to interleukin-12.
Ulchaker J; Panuto J; Rayman P; Novick A; Elson P; Tubbs R; Finke JH; Bukowski RM
J Immunother; 1999 Jan; 22(1):71-9. PubMed ID: 9924702
[TBL] [Abstract][Full Text] [Related]
6. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors.
Alexander JP; Kudoh S; Melsop KA; Hamilton TA; Edinger MG; Tubbs RR; Sica D; Tuason L; Klein E; Bukowski RM
Cancer Res; 1993 Mar; 53(6):1380-7. PubMed ID: 8443817
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma.
Mulders P; Tso CL; Pang S; Kaboo R; McBride WH; Hinkel A; Gitlitz B; Dannull J; Figlin R; Belldegrun A
J Immunother; 1998 May; 21(3):170-80. PubMed ID: 9610908
[TBL] [Abstract][Full Text] [Related]
8. Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma.
Nakagomi H; Pisa P; Pisa EK; Yamamoto Y; Halapi E; Backlin K; Juhlin C; Kiessling R
Int J Cancer; 1995 Nov; 63(3):366-71. PubMed ID: 7591233
[TBL] [Abstract][Full Text] [Related]
9. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.
Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Ceuppens JL
Clin Exp Immunol; 1997 Sep; 109(3):501-9. PubMed ID: 9328129
[TBL] [Abstract][Full Text] [Related]
10. Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation.
Finke JH; Rayman P; Hart L; Alexander JP; Edinger MG; Tubbs RR; Klein E; Tuason L; Bukowski RM
J Immunother Emphasis Tumor Immunol; 1994 Feb; 15(2):91-104. PubMed ID: 7907918
[TBL] [Abstract][Full Text] [Related]
11. Semiquantitative analysis of Th1 and Th2 cytokine expression in CD3+, CD4+, and CD8+ renal-cell-carcinoma-infiltrating lymphocytes.
Elsässer-Beile U; Grussenmeyer T; Gierschner D; Schmoll B; Schultze-Seemann W; Wetterauer U; Schulte Mönting J
Cancer Immunol Immunother; 1999 Jul; 48(4):204-8. PubMed ID: 10431690
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the immune reactivity of infiltrating and peripheral lymphocytes from patients with renal cell carcinoma by measuring cytokine secretion.
Elsässer-Beile U; Wetterauer U; Schultze-Seemann W; Gallati H; Mönting JS; von Kleist S
Cancer Immunol Immunother; 1996 Feb; 42(2):93-8. PubMed ID: 8620526
[TBL] [Abstract][Full Text] [Related]
13. Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.
Belldegrun A; Tso CL; Kaboo R; Pang S; Pierce W; deKernion JB; Figlin R
J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):149-61. PubMed ID: 8732698
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of interleukin-2 and CD3 triggering on cytokine gene transcription and secretion in cultured tumor infiltrating lymphocytes.
Filgueira L; Zuber M; Juretic A; Lüscher U; Caetano V; Harder F; Garotta G; Heberer M; Spagnoli GC
Cell Immunol; 1993 Aug; 150(1):205-18. PubMed ID: 8343966
[TBL] [Abstract][Full Text] [Related]
15. The cytokine microenvironment of human colon carcinoma. Lymphocyte expression of tumor necrosis factor-alpha and interleukin-4 predicts improved survival.
Barth RJ; Camp BJ; Martuscello TA; Dain BJ; Memoli VA
Cancer; 1996 Sep; 78(6):1168-78. PubMed ID: 8826937
[TBL] [Abstract][Full Text] [Related]
16. Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo.
Steger GG; Pierce WC; Figlin R; Czernin J; Kaboo R; DeKernion JB; Okarma T; Belldegrun A
Clin Immunol Immunopathol; 1994 Aug; 72(2):237-47. PubMed ID: 8050198
[TBL] [Abstract][Full Text] [Related]
17. The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes.
Lüscher U; Filgueira L; Juretic A; Zuber M; Lüscher NJ; Heberer M; Spagnoli GC
Int J Cancer; 1994 May; 57(4):612-9. PubMed ID: 8181865
[TBL] [Abstract][Full Text] [Related]
18. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
19. Different expression of Fas and Fas ligand in tumor infiltrating and peripheral lymphocytes of patients with renal cell carcinomas.
Elsässer-Beile U; Gierschner D; Welchner T; Wetterauer U
Anticancer Res; 2003; 23(1A):433-7. PubMed ID: 12680244
[TBL] [Abstract][Full Text] [Related]
20. Functional and molecular characterization of tumour-infiltrating lymphocytes and clones thereof from a major-histocompatibility-complex-negative human tumour: neuroblastoma.
Facchetti P; Prigione I; Ghiotto F; Tasso P; Garaventa A; Pistoia V
Cancer Immunol Immunother; 1996 Mar; 42(3):170-8. PubMed ID: 8640845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
